Cardiopoietic stem cell therapy restores infarction-altered cardiac proteome
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Cardiopoietic stem cells have reached advanced clinical testing for ischemic heart failure. To profile their molecular influence on recipient hearts, systems proteomics was here applied in a chronic model of infarction randomized with and without human cardiopoietic stem cell treatment. Multidimensional label-free tandem mass spectrometry resolved and quantified 3987 proteins constituting the cardiac proteome. Infarction altered 450 proteins, reduced to 283 by stem cell treatment. Notably, cell therapy non-stochastically reversed a majority of infarction-provoked changes, remediating 85% of disease-affected protein clusters. Pathway and network analysis decoded functional reorganization, distinguished by prioritization of vasculogenesis, cardiac development, organ regeneration, and differentiation. Subproteome restoration nullified adverse ischemic effects, validated by echo-/electro-cardiographic documentation of improved cardiac chamber size, reduced QT prolongation and augmented ejection fraction post-cell therapy. Collectively, cardiopoietic stem cell intervention transitioned infarcted hearts from a cardiomyopathic trajectory towards pre-disease. Systems proteomics thus offers utility to delineate and interpret complex molecular regenerative outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





![Fig. 6 Cardiopoietic cell therapy redirects infarction modified proteome toward pre-disease state. a Principal component (PC) analysis of differential protein expression segregated myocardial infarction hearts (MI, blue) away from pre-disease controls (Ctrl, red), with cardiopoietic cell therapy (MI + CP, green) counterparts positioned in-between. PC1 represents 25%, PC2 13%, and PC3 11% of total data. b Euclidean squared distance between cohorts was maximal for MI versus Ctrl (2.28 × 105) representing the full extent of disease induced transition, i.e., 100% displacement. Distance between cardiopoietic cell therapy cohort and control (MI + CP versus Ctrl) was substantially lower (1.18 × 105), i.e., 52% of disease-induced displacement. Moreover, the MI + CP versus MI distance was 1.59 × 105, estimating that treatment outcome (MI + CP) response displacement returned ≈57% of the way [1.18 × 105/(1.18 × 105 + 1.59 × 105)] toward pre-disease.](https://figures.cochat.ai/paper-figures/af21415efb3c4c96987122a4de049ee9/cardiopoietic-stem-cell-therapy-restores-infarction-altered-cardiac-proteome-figure-6.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“proximity labelling to assess protein–protein interactions involved in β-adrenergic signalling of contractility in cardiac fight-or-flight responses124 and evaluation of regenerative stem cell therapy efficacy in post-infarct hearts125.”
From A high-stringency blueprint of the human proteome (2020) · cites this paper as [125]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cytoscape: A software Environment for integrated models of biomolecular interaction networks
Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin, N., Schwikowski, B., & Ideker, T. (2003) · Genome Research · doi:10.1101/gr.1239303 · Cited by 51,888
Perez-Riverol, Y., Csordas, A., Bai, J., Bernal-Llinares, M., Hewapathirana, S., Kundu, D. J., Inuganti, A., Griss, J., Mayer, G., Eisenacher, M., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1106 · Cited by 6,693
The MaxQuant computational platform for mass spectrometry-based shotgun proteomics
Tyanova, S., Temu, T., & Cox, J. (2016) · Nature Protocols · doi:10.1038/nprot.2016.136 · Cited by 4,797
Maere, S., Heymans, K., & Kuiper, M. (2005) · Bioinformatics · doi:10.1093/bioinformatics/bti551 · Cited by 4,155
Metsalu, T., & Vilo, J. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv468 · Cited by 3,709
Mass-spectrometric exploration of proteome structure and function
Aebersold, R., & Mann, M. (2016) · Nature · doi:10.1038/nature19949 · Cited by 2,334
Hass, R., Kasper, C., Böhm, S., & Jacobs, R. (2011) · Cell Communication and Signaling · doi:10.1186/1478-811x-9-12 · Cited by 1,748
Proteogenomics connects somatic mutations to signalling in breast cancer
CPTAC, N., Mertins, P., Mani, D. R., Ruggles, K. V., Gillette, M. A., Clauser, K. R., Wang, P., Wang, X., Qiao, J. W., Cao, S., et al. (2016) · Nature · doi:10.1038/nature18003 · Cited by 1,676
The Translational Landscape of the Human Heart
van Heesch, S., Witte, F., Schneider-Lunitz, V., Schulz, J. F., Adami, E., Faber, A. B., Kirchner, M., Maatz, H., Blachut, S., Sandmann, C.-L., et al. (2019) · Cell · doi:10.1016/j.cell.2019.05.010 · Cited by 626
An acute immune response underlies the benefit of cardiac stem cell therapy
Vagnozzi, R. J., Maillet, M., Sargent, M. A., Khalil, H., Johansen, A. K. Z., Schwanekamp, J. A., York, A. J., Huang, V., Nahrendorf, M., Sadayappan, S., et al. (2020) · Nature · doi:10.1038/s41586-019-1802-2 · Cited by 554
Cited by
A high-stringency blueprint of the human proteome
Adhikari, S., Nice, E. C., Deutsch, E. W., Lane, L., Omenn, G. S., Pennington, S. R., Paik, Y.-K., Overall, C. M., Corrales, F. J., Cristea, I. M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19045-9 · Cited by 210
Minimally invasive delivery of a hydrogel-based exosome patch to prevent heart failure
Cheng, G., Zhu, D., Huang, K., & Caranasos, T. G. (2022) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2022.04.020 · Cited by 69
Jiang, F.-Q., Liu, K., Chen, J., Cao, Y., Chen, W.-Y., Zhao, W.-L., Song, G., Liang, C.-Q., Zhou, Y.-M., Huang, H., et al. (2022) · eLife · doi:10.7554/elife.77014 · Cited by 47
Emerging technologies for cardiac tissue engineering and artificial hearts
Sun, L., Wang, Y., Xu, D., & Zhao, Y. (2023) · Smart Medicine · doi:10.1002/smmd.20220040 · Cited by 44
Regenerative Medicine Clinical Readiness
Yamada, S., Behfar, A., & Terzic, A. (2021) · Regenerative Medicine · doi:10.2217/rme-2020-0178 · Cited by 37
Self-citation
Metadata
- Authors
- Arrell, D. K., Rosenow, C. S., Yamada, S., Behfar, A., & Terzic, A.
- Affiliations
- Mayo Clinic (US)
- Venue
- npj Regenerative Medicine
- Published
- 2020-03-12
- Volume
- 5
- Issue
- 1
- Pages
- 5-5
- ISSN
- 2057-3995 (ISSN-L)
- PMC
- PMC7067830
- OpenAlex
- W3012451848
- Cited by
- 30
- References
- 69
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 4 · 2023: 4 · 2022: 5 · 2021: 7 · 2020: 4
- FWCI
- 2.59
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- npj Regenerative Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Regenerative Medicine Minnesota (021218BT001)
- National Institutes of Health (HL-07111)
- National Heart, Lung, and Blood Institute (R01HL134664, T32HL007111)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Congenital heart defects research
- Health Sciences › Medicine › Surgery › Tissue Engineering and Regenerative Medicine
- Keywords
- stem cell therapy, myocardial infarction, cardiac proteome, ischemic heart failure, vasculogenesis, cardiac regeneration, heart development, ejection fraction, QT prolongation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cardiopoietic stem cell therapy restores infarction-altered cardiac proteome. https://app.cochat.ai/papers/10.1038/s41536-020-0091-6
- The paper
- Arrell, D. K., Rosenow, C. S., Yamada, S., Behfar, A., & Terzic, A. (2020). Cardiopoietic stem cell therapy restores infarction-altered cardiac proteome. npj Regenerative Medicine. https://doi.org/10.1038/s41536-020-0091-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.